INT32677

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1988
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 3.10
Pain Relevance 1.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Npepo) cytoplasm (Npepo)
Anatomy Link Frequency
nerves 1
lymph 1
striatum 1
apoptotic cells 1
Npepo (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dynorphin 12 99.84 Very High Very High Very High
qutenza 9 99.14 Very High Very High Very High
agonist 12 99.00 Very High Very High Very High
Dopamine 11 98.82 Very High Very High Very High
nMDA receptor antagonist 1 96.40 Very High Very High Very High
Morphine 1 94.72 High High
anesthesia 5 94.40 High High
narcan 4 93.00 High High
imagery 34 90.92 High High
Opioid 3 81.20 Quite High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 60 100.00 Very High Very High Very High
Apoptosis 69 99.68 Very High Very High Very High
Body Weight 3 95.92 Very High Very High Very High
Hyperlipidemia 8 92.68 High High
Fistula 2 89.12 High High
Aging 5 88.24 High High
Death 17 84.32 Quite High
INFLAMMATION 5 61.00 Quite High
Sepsis 11 54.36 Quite High
Postmenopausal Osteoporosis 15 52.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
On the following day, lipid emulsion containing 35.4 mg/h of olive oil was infused intraduodenally for 7 h and lymph collected hourly was assayed for triglyceride and apolipoprotein A-IV (apo A-IV).
Positive_regulation (assayed) of apo in lymph associated with disorder of lipid metabolism
1) Confidence 0.49 Published 2000 Journal Mech. Ageing Dev. Section Abstract Doc Link 10714940 Disease Relevance 0.26 Pain Relevance 0.09
These results do not support a role for capsaicin-sensitive, sensory afferent nerves in the stimulation of intestinal apo A-IV by dietary lipid.
Positive_regulation (stimulation) of apo in nerves associated with qutenza
2) Confidence 0.45 Published 1997 Journal Am. J. Physiol. Section Abstract Doc Link 9321877 Disease Relevance 0.29 Pain Relevance 0.63
When repeated injections of AMPH were given only one day, the diminished stereotypy response to AMPH or APO was not observed.
Positive_regulation (response) of APO
3) Confidence 0.37 Published 1988 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 2976168 Disease Relevance 0 Pain Relevance 0.47
While co-administration of the NMDA receptor antagonist, MK-801, inhibited APO-induced increases in DYN and Fos/FRA expression in the intact striatum, its only effect in the DA-denervated striatum was a partial (35%) inhibition of the APO-induced increase in DYN-ir concentrations.
Positive_regulation (increase) of APO in striatum associated with dopamine, nmda receptor antagonist and dynorphin
4) Confidence 0.32 Published 1994 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 7914658 Disease Relevance 0 Pain Relevance 0.44
Hence, the proposed Tier I battery needs to be further evaluated with higher dosages of APO and other D(2) receptor agonists to determine whether it is capable of detecting such agents.
Positive_regulation (dosages) of APO associated with agonist
5) Confidence 0.13 Published 2000 Journal Reprod. Toxicol. Section Abstract Doc Link 10838120 Disease Relevance 0.10 Pain Relevance 0.22
Accumulation of ApoSense within apoptotic cells can contribute to amplification of the signal obtained and consequently to the high signal-to-noise ratio.
Positive_regulation (Accumulation) of ApoSense in apoptotic cells associated with apoptosis
6) Confidence 0.12 Published 2005 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC1998881 Disease Relevance 0.93 Pain Relevance 0.05
Lasofoxifene resulted in significantly greater decreases in total serum cholesterol and apolipoprotein (Apo) B-100, and a significantly greater increase in Apo A-1, compared with raloxifene, while there were no significant changes in high-density lipoprotein (HDL) cholesterol or triglycerides in any group.
Positive_regulation (increase) of Apo associated with disorder of lipid metabolism
7) Confidence 0.08 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2773750 Disease Relevance 0.51 Pain Relevance 0.03
Administration of pitavastatin produced a significant and sustained increase of the serum HDL-C levels (from 36.0 ± 5.9 mg/dL at baseline to 40.5 ± 9.1 mg/dL at 12 months, P < 0.001) and Apo A-I levels (from 108.4 ± 18.0 mg/dL to 118.7 ± 19.3 mg/dL, P < 0.01).61 In a clinical study conducted to confirm the effect of pitavastatin on the HDL metabolism,30 29 patients with hypercholesterolemia were treated with pitavastatin 2 mg for 4 weeks.
Positive_regulation (increase) of Apo associated with hyperlipidemia and disorder of lipid metabolism
8) Confidence 0.03 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2788597 Disease Relevance 1.01 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox